Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dinah Sah, Bernard Ravina, David Rodman, Casi DeYoung

Premium

Voyager Therapeutics, a startup developing adeno-associated viral vector therapies, including RNAi-based ones, for central nervous system disorders, has named Dinah Sah as its senior vice president of neuroscience.

Sah was previously vice president of research at Alnylam Pharmaceuticals.

Voyager has also appointed Bernard Ravina to the position of vice president of clinical development. He most recently was medical director of clinical development at Biogen Idec.


MiRagen Therapeutics has named David Rodman as executive vice president of research and development.

Rodman was most recently vice president of clinical development at Vertex Pharmaceuticals.


Mirna Therapeutics said it has named Casi DeYoung as its chief business officer.

Previously, DeYoung was vice president of business development at ODC Therapy.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.